Stock listing

NASDAQ:SUPN Supernus Pharmaceuticals, Inc. Stock

Home listing (NASDAQ) of Supernus Pharmaceuticals, Inc.

Follow Supernus Pharmaceuticals, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:SUPN

$28.61 USD -0.35 (-1.2%)

Close on Nov 20, 2026

Past year -9.9% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$28.15 – $29.51 USDNov 20, 2026
Volume
2.83M sharesNov 20, 2026
Market cap
$1.67B USDAt the close on Nov 20, 2026 · price × 58.22M shares outstanding
52-week range
$25.92 – $42.81 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$89.36M USDMedian day 2.22M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Supernus Pharmaceuticals, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:SUPN · Home$28.61 USD-0.35 (-1.2%)2,831,327$28.39$29.51$28.15$28.96Close on Nov 20, 2026
LSE:0LB2$30.33 USD-12.44 (-29.1%)42$30.33$30.33$30.33$42.77Close on Nov 3, 2026
Frankfurt:S49€24.48 EUR+1.251 (+5.4%)2€24.48€24.48€24.48€23.23Close on Nov 5, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:SUPN · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$28.61-0.35-1.2%$28.39$29.51$28.152,831,327
$28.96-0.08-0.3%$29.21$29.75$28.692,714,267
$29.04+0.21+0.7%$28.72$29.69$28.462,810,120
$28.83-0.89-3.0%$29.43$29.61$28.403,782,231
$29.72+0.52+1.8%$29.41$29.92$28.822,071,488
$29.20-0.25-0.8%$29.48$30.17$28.794,365,750
$29.45+0.70+2.4%$28.75$29.66$28.713,072,550
$28.75+1.13+4.1%$27.61$28.83$27.332,784,892
$27.62+1.46+5.6%$26.54$27.91$26.112,574,732
$26.16-0.58-2.2%$26.58$27.08$25.924,363,419
$26.74-1.47-5.2%$28.29$28.79$26.526,080,379
$28.21+0.06+0.2%$26.81$28.99$26.746,565,162
$28.15-8.13-22.4%$28.35$31.62$27.979,053,152
$36.28+0.91+2.6%$35.43$37.02$35.324,869,435
$35.37+0.12+0.3%$34.78$36.49$34.624,607,200
$35.25+0.48+1.4%$36.53$37.00$34.535,718,700
$34.77+0.05+0.1%$34.39$34.86$33.841,529,600
$34.72+0.16+0.5%$34.68$34.82$33.932,410,600
$34.56+0.09+0.3%$34.47$34.65$33.99916,600
$34.47-0.86-2.4%$35.35$35.35$34.101,484,000
$35.33+0.54+1.6%$34.77$35.36$34.54871,700
$34.79+0.02+0.1%$34.92$35.15$34.563,344,500
$34.77+0.90+2.7%$34.02$35.12$33.801,925,300
$33.87+1.42+4.4%$32.60$34.19$32.482,276,300
$32.45-1.17-3.5%$33.47$33.84$32.314,291,100
$33.62-0.54-1.6%$34.57$34.86$33.541,751,000
$34.16-1.26-3.6%$35.11$36.30$33.992,781,200
$35.42-0.64-1.8%$36.09$36.26$35.191,930,400
$36.06+0.23+0.6%$36.00$36.32$35.377,474,000
$35.83+0.38+1.1%$35.45$36.14$35.214,799,600
$35.45-0.68-1.9%$35.73$36.35$34.851,527,200
$36.13+0.23+0.6%$35.58$36.30$35.581,769,600
$35.90-0.09-0.3%$35.96$36.15$35.032,390,500
$35.99+0.28+0.8%$36.00$36.26$35.733,003,300
$35.71+0.33+0.9%$35.46$36.15$35.261,669,300
$35.38-0.47-1.3%$35.85$36.21$35.251,879,000
$35.85-0.74-2.0%$36.54$36.60$35.791,673,600
$36.59-0.29-0.8%$36.74$37.05$36.082,005,500
$36.88+1.06+3.0%$35.50$36.96$35.431,173,500
$35.82-0.18-0.5%$35.90$36.22$35.721,098,400
$36.00+0.09+0.3%$35.71$36.28$35.572,221,700
$35.91-0.28-0.8%$36.23$36.90$35.781,058,000
$36.19+0.66+1.9%$35.53$36.63$35.482,216,100
$35.53+0.65+1.9%$35.00$35.63$34.771,299,000
$34.88-0.81-2.3%$35.59$35.62$34.594,684,200
$35.69+1.34+3.9%$34.76$35.90$34.472,690,500
$34.35+0.13+0.4%$33.97$34.54$33.841,865,900
$34.22-0.25-0.7%$34.59$34.59$33.742,700,600
$34.47-0.02-0.1%$34.74$35.01$34.153,429,300
$34.49-0.02-0.1%$34.49$34.83$34.231,297,200
$34.51-0.26-0.7%$34.58$34.87$34.041,319,500
$34.77+0.45+1.3%$34.32$34.80$33.921,351,700
$34.32-0.62-1.8%$34.35$34.84$33.841,823,800
$34.94+0.11+0.3%$34.74$35.31$34.551,019,400
$34.83-0.22-0.6%$35.18$35.23$34.571,825,600
$35.05+0.49+1.4%$34.74$35.28$34.682,975,000
$34.56-0.37-1.1%$35.00$35.44$34.502,094,800
$34.93+0.06+0.2%$34.87$35.30$34.331,963,300
$34.87-0.43-1.2%$35.31$35.49$34.493,308,700
$35.30-0.525-1.5%$35.61$35.95$35.111,220,400
$35.83-0.145-0.4%$35.90$36.21$35.551,275,300
$35.97-0.21-0.6%$36.23$36.75$35.611,712,100
$36.18-0.69-1.9%$36.53$36.82$35.371,840,800
$36.87-0.91-2.4%$37.68$38.52$36.702,496,700
$37.78-1.26-3.2%$38.91$39.25$37.641,442,300

Splits

1 split · NASDAQ:SUPN · every price before a split is adjusted for it

DayRatioWhat
1-for-5Consolidation
Ticker
NASDAQ:SUPN
Asset type
Stock
Sector
Health care
Industry
Pharmaceuticals
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Supernus Pharmaceuticals, Inc. news

Supernus Pharmaceuticals, Inc. on 6ix

Sector
Health care
Industry
Pharmaceuticals
News releases
20 in the last 12 months · 162 in all · newest Nov 10, 2026 · oldest 2019
Calls
25 calls with a replay · 25 with a transcript · latest Oct 29, 2026
Decks
18 decks · latest Oct 29, 2026

Where Supernus Pharmaceuticals, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:SUPN · Home listing · This pageNASDAQUnited StatesUSD
Lang & Schwarz:A1JX3ULang & SchwarzGermanyEUR
LS Exchange:A1JX3ULS ExchangeGermanyEUR
gettex:S49gettexGermanyEUR
BOATS:SUPNBOATSUnited StatesUSD
LSE:0LB2LSEUnited KingdomUSD
Frankfurt:S49FrankfurtGermanyEUR
BX Swiss:S49BX SwissSwitzerlandCHF
Dusseldorf:S49DusseldorfGermanyEUR
Munich:S49MunichGermanyEUR
Stuttgart:S49StuttgartGermanyEUR
Tradegate:S49TradegateGermanyEUR

Valuation

P/E 3.7× against a median of 18.5×: the lowest of 9 Pharmaceuticals companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$1.85B USD
P/E
3.7×
EV/sales
1.4×
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
Negative equity
Gross margin
85.1%
Operating margin
40.6%
Net margin
32.9%
Debt to equity
Negative equity
Beta vs S&P 500
0.67

Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Supernus Pharmaceuticals, Inc. · NASDAQ:SUPNUS$1.67BUS$1.85B3.7×1.4×n/an/a32.9%n/a0.67
Harbin Pharmaceutical Group Co., Ltd. Class A · SSE:600664US$1.70BUS$1.22B17.9×0.5×n/a1.8×3.9%0.0×n/a
Mayinglong Pharmaceutical Group Co., Ltd. Class A · SSE:600993US$1.70BUS$1.34B19.1×2.2×n/a2.5×14.9%0.0×n/a
Ultragenyx Pharmaceutical Inc. · NASDAQ:RAREUS$1.68BUS$2.60Bn/a3.6×n/an/a−71.8%n/a1.35
Caplin Point Laboratories Limited · NSE:CAPLIPOINTUS$1.66BUS$1.56B23.2×6.3×18.1×4.3×29.1%0.0×n/a
AstraZeneca Pharma India Limited · NSE:ASTRAZENUS$1.66BUS$1.60B86.8×5.7×59.3×17.5×6.8%0.0×n/a
Hugel, Inc. · KRX:145020US$1.66BUS$1.21B14.1×3.4×7.1×2.1×32.9%0.0×n/a
Agios Pharmaceuticals, Inc. · NASDAQ:AGIOUS$1.65BUS$1.05Bn/a7.4×n/a1.7×−264.8%0.0×1.10
Faes Farma, S.A. · BME:FAEUS$1.65BUS$1.93B11.0×1.7×5.8×1.9×13.1%0.5×n/a
Consun Pharmaceutical Group Ltd. · HKEX:1681US$1.64BUS$1.07B10.1×2.1×5.6×2.3×31.6%0.1×n/a
BrightGene Bio-Medical Technology Co. Ltd. Class A · SSE:688166US$1.63BUS$1.68B106×8.3×n/a3.5×7.6%0.5×n/a
Median of the othersUS$1.66BUS$1.45B18.5×3.5×7.1×2.3×10.3%0.0×1.23

Forecasts

3 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 10, 2026. Not 6ix's view and not investment advice.

Price target
55.33 USD · Analysts' mean
EPS, year to Dec 2026
3.44 · 1 analyst
Revenue, year to Dec 2026
1.68B · 2 analysts

Team and board

Officers

OfficerRole
Jack A. KhattarPresident and Chief Executive Officer, Director
Timothy C. DecSenior Vice President, Chief Financial Officer
Bryan A. RoeckleinSenior Vice President, Chief Business Officer
Frank MottolaSenior Vice President, Chief Technical Operations Officer
Jeff BozickSenior Vice President, Supply Chain
Jonathan RubinSenior Vice President, Chief Medical Officer, Research & Development
Padmanabh P. BhattSenior Vice President, Chief Scientific Officer, Intellectual Property
Roman BradelVice President, Regulatory Affairs
Taylor RaifordSenior Vice President, Sales
Todd HorichSenior Vice President, Chief Commercial Officer
Kevin EspinozaChief Integrity and Compliance Officer

Board

DirectorRole
Bethany SensenigINDEPENDENT NON-EXECUTIVE DIRECTOR
Carrolee BarlowINDEPENDENT NON-EXECUTIVE DIRECTOR
Georges GemayelINDEPENDENT NON-EXECUTIVE DIRECTOR
Jack A. KhattarPresident and Chief Executive Officer, Director
Juliet ThompsonINDEPENDENT NON-EXECUTIVE DIRECTOR
Keith HumphreysINDEPENDENT NON-EXECUTIVE DIRECTOR
Mark StejbachINDEPENDENT NON-EXECUTIVE DIRECTOR

Events

Calls

CallWhenStatus
Supernus Pharmaceuticals (NASDAQ:SUPN) Q3 2026 Earnings CallThu, Oct 29, 2026 · 4:30 PM ETReplay
Supernus Pharmaceuticals (NASDAQ:SUPN) Q2 2026 Earnings CallTue, Aug 04, 2026 · 4:30 PM ETReplay
Supernus Pharmaceuticals (NASDAQ:SUPN) Q1 2026 Earnings CallTue, May 05, 2026 · 4:30 PM ETReplay
Supernus Pharmaceuticals (NASDAQ:SUPN) Q4 2025 Earnings CallTue, Feb 24, 2026 · 4:30 PM ETReplay
Supernus Pharmaceuticals (NASDAQ:SUPN) Q3 2025 Earnings CallTue, Nov 04, 2025 · 4:30 PM ETReplay
Supernus Pharmaceuticals (NASDAQ:SUPN) Q2 2025 Earnings CallTue, Aug 05, 2025 · 4:30 PM ETReplay
Supernus Pharmaceuticals (NASDAQ:SUPN) Q1 2025 Earnings CallTue, May 06, 2025 · 4:30 PM ETReplay
Supernus Pharmaceuticals (NASDAQ:SUPN) Q4 2024 Earnings CallTue, Feb 25, 2025 · 4:30 PM ETReplay
Supernus Pharmaceuticals (NASDAQ:SUPN) Q3 2024 Earnings CallMon, Nov 04, 2024 · 4:30 PM ETReplay
Supernus Pharmaceuticals (NASDAQ:SUPN) Q2 2024 Earnings CallTue, Aug 06, 2024 · 4:30 PM ETReplay
All 25 calls
CallWhenStatus
Supernus Pharmaceuticals (NASDAQ:SUPN) Q1 2024 Earnings CallWed, May 08, 2024 · 4:30 PM ETReplay
Supernus Pharmaceuticals (NASDAQ:SUPN) Q4 2023 Earnings CallTue, Feb 27, 2024 · 4:30 PM ETReplay
Supernus Pharmaceuticals (NASDAQ:SUPN) Q3 2023 Earnings CallWed, Nov 08, 2023 · 4:30 PM ETReplay
Supernus Pharmaceuticals (NASDAQ:SUPN) Q2 2023 Earnings CallTue, Aug 08, 2023 · 4:30 PM ETReplay
Supernus Pharmaceuticals (NASDAQ:SUPN) Q1 2023 Earnings CallTue, May 09, 2023 · 4:30 PM ETReplay
Supernus Pharmaceuticals (NASDAQ:SUPN) Q4 2022 Earnings CallTue, Feb 28, 2023 · 4:30 PM ETReplay
Supernus Pharmaceuticals (NASDAQ:SUPN) Q3 2022 Earnings CallTue, Nov 08, 2022 · 4:30 PM ETReplay
Supernus Pharmaceuticals (NASDAQ:SUPN) Q2 2022 Earnings CallThu, Aug 04, 2022 · 4:30 PM ETReplay
Supernus Pharmaceuticals (NASDAQ:SUPN) Q1 2022 Earnings CallMon, May 09, 2022 · 4:30 PM ETReplay
Supernus Pharmaceuticals (NASDAQ:SUPN) Q4 2021 Earnings CallMon, Feb 28, 2022 · 4:30 PM ETReplay
Supernus Pharmaceuticals (NASDAQ:SUPN) Q3 2021 Earnings CallWed, Nov 03, 2021 · 4:30 PM ETReplay
Supernus Pharmaceuticals (NASDAQ:SUPN) Q2 2021 Earnings CallWed, Aug 04, 2021 · 4:30 PM ETReplay
Supernus Pharmaceuticals (NASDAQ:SUPN) Q1 2021 Earnings CallWed, May 05, 2021 · 4:30 PM ETReplay
Supernus Pharmaceuticals (NASDAQ:SUPN) Q4 2020 Earnings CallThu, Feb 25, 2021 · 4:30 PM ETReplay
Supernus Pharmaceuticals (NASDAQ:SUPN) Q3 2020 Earnings CallWed, Nov 04, 2020 · 9:00 AM ETReplay

Results days

QuarterResultsShare move
Q3 2026Oct 29, 2026 · After close+0.3%
Q2 2026Aug 3, 2026 · Before open−6.6%
Q1 2026May 5, 2026 · After close+2.6%
Q4 2025Mar 3, 2026+0.6%
Q3 2025Nov 4, 2025 · After close+0.2%
Q2 2025Aug 5, 2025 · After close+0.9%
Q1 2025May 6, 2025 · After close−1.9%
Q4 2024Feb 25, 2025 · Before open+0.1%
Q3 2024Nov 4, 2024 · After close+0.3%
Q2 2024Aug 6, 2024 · After close−2.2%
All 20 quarters
QuarterResultsShare move
Q1 2024May 8, 2024 · After close+0.5%
Quarter to Dec 31, 2023Feb 27, 2024 · After close−1.6%
Quarter to Sep 30, 2023Nov 8, 2023 · After close−5.5%
Quarter to Jun 30, 2023Aug 8, 2023 · After close+1.1%
Quarter to Mar 31, 2023May 9, 2023 · After close0.0%
Quarter to Dec 31, 2022Feb 28, 2023 · After close−3.7%
Quarter to Sep 30, 2022Nov 8, 2022 · After close0.0%
Quarter to Jun 30, 2022Aug 4, 2022 · After close0.0%
Quarter to Mar 31, 2022May 9, 2022 · After close−2.4%
Quarter to Dec 31, 2021Feb 28, 2022 · After close0.0%

Open Events

Decks

DeckKindSlidesDate
Q3 2026 Earnings PresentationEarnings7 slidesOct 29, 2026
Merger or Acquisition (August 2026)Merger or acquisition11 slidesAug 3, 2026
Merger or Acquisition (August 2026)Merger or acquisition13 slidesAug 3, 2026
Investor Presentation (May 2026)Investor deck35 slidesMay 2026
Merger or Acquisition (June 2025)Merger or acquisition16 slidesJun 16, 2025
Q1 2025 Earnings PresentationEarnings32 slidesMay 6, 2025
Investor Day (October 2023)Investor day104 slidesOct 18, 2023
Jefferies Healthcare Conference 2022Conference23 slidesJun 9, 2022
Merger or Acquisition (October 2021)Merger or acquisition19 slidesOct 12, 2021
Technical Presentation (December 2020)Technical8 slidesDec 23, 2020
All 18 decks
DeckKindSlidesDate
Merger or Acquisition (May 2020)Merger or acquisition26 slidesMay 4, 2020
Corporate Update (March 2019)Corporate update14 slidesMar 28, 2019
Corporate Update (December 2018)Corporate update32 slidesDec 10, 2018
Debt Investor Presentation (March 2018)Debt investors35 slidesMar 14, 2018
Corporate Update (October 2016)Corporate update12 slidesOct 11, 2016
Investor Presentation (March 2015)Investor deck20 slidesMarch 2015
Investor Presentation (April 2013)Investor deck32 slidesApr 26, 2013
Stifel and Rodman & Renshaw Conferences 2012Conference19 slidesSeptember 2012

Open Decks

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022
Revenue1.24B1.19B1.09B901.0M
Cost of revenue246.0M231.0M174.0M151.0M
Gross profit994.0M957.0M919.0M749.0M
Research and development97.0M107.0M116.0M74.0M
Selling, general and administrative634.0M612.0M565.0M466.0M
Operating income262.0M38.0M-152.0M-77.0M
Depreciation and amortization10.0M16.0M15.0M16.0M
EBITDA272.0M54.0M-137.0M-61.0M
Interest expense45.0M41.0M35.0M27.0M
Income before tax239.0M20.0M-145.0M-86.0M
Income tax29.0M13.0M-19.0M-43.0M
Net income210.0M7.00M-126.0M-42.0M
Earnings per share, basic1.680.05-0.92-0.30
Earnings per share, diluted1.640.05-0.92-0.30

Balance sheet

LineFY2025FY2024FY2023FY2022
Cash and equivalents195.0M319.0M316.0M774.0M
Short-term investments01.00M94.0M
Receivables253.0M254.0M254.0M
Inventory153.0M167.0M126.0M
Current assets652.0M827.0M1.26B
Property, plant and equipment144.0M100.0M84.0M
Goodwill2.00M2.00M5.00M
Total assets1.20B1.32B1.76B
Accounts payable48.0M63.0M39.0M
Current liabilities914.0M924.0M1.28B
Long-term debt290.0M315.0M237.0M
Total debt319.0M333.0M240.0M
Total liabilities1.30B1.65B1.94B
Shareholders' equity-98.0M-337.0M-184.0M-15.0M
Shares outstanding118.0M118.0M125.1M125.1M

Cash flow

LineFY2025FY2024FY2023FY2022
Cash from operations-27.0M36.0M-300.0M-4.00M
Capital spending-66.0M-29.0M-8.00M-5.00M
Free cash flow-93.0M7.00M-308.0M-9.00M
Cash from investing-66.0M69.0M-95.0M-222.0M
Cash from financing-30.0M-102.0M-64.0M-101.0M
Share buybacks-11.0M-173.0M-33.0M-90.0M
Change in cash-124.0M3.00M-459.0M-327.0M

Open Financials

Filings

FilingDateTypeFiled with
4 · Change in ownershipNov 4, 2026Insider tradeSEC
4 · Change in ownershipNov 4, 2026Insider tradeSEC
4 · Change in ownershipNov 4, 2026Insider tradeSEC
4 · Change in ownershipNov 4, 2026Insider tradeSEC
4 · Change in ownershipNov 4, 2026Insider tradeSEC
4 · Change in ownershipNov 4, 2026Insider tradeSEC
4 · Change in ownershipNov 4, 2026Insider tradeSEC
4 · Change in ownershipNov 4, 2026Insider tradeSEC
4 · Change in ownershipNov 4, 2026Insider tradeSEC
3 · Initial statement of ownershipNov 4, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
3 · Initial statement of ownershipNov 4, 2026Insider tradeSEC
3 · Initial statement of ownershipNov 4, 2026Insider tradeSEC
3 · Initial statement of ownershipNov 4, 2026Insider tradeSEC
3 · Initial statement of ownershipNov 4, 2026Insider tradeSEC
3 · Initial statement of ownershipNov 4, 2026Insider tradeSEC
3 · Initial statement of ownershipNov 4, 2026Insider tradeSEC
3 · Initial statement of ownershipNov 4, 2026Insider tradeSEC
3 · Initial statement of ownershipNov 4, 2026Insider tradeSEC
8-K · Current reportNov 3, 2026Current reportSEC
8-K · Current reportNov 2, 2026Acquisition or disposalSEC
10-Q · Quarterly reportOct 29, 2026Quarterly reportSEC
425Oct 29, 2026Other filingsSEC
8-K · Current reportOct 29, 2026ResultsSEC
8-K · Current reportOct 15, 2026Meeting outcomeSEC
425Oct 6, 2026Other filingsSEC
8-K · Current reportOct 6, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeSep 30, 2026Big-stake noticeSEC
425Sep 17, 2026Other filingsSEC
8-K · Current reportSep 17, 2026Current reportSEC
8-K · Current reportSep 15, 2026Current reportSEC
EFFECT · Notice that a registration is effectiveSep 14, 2026Other filingsSEC
424B3 · ProspectusSep 11, 2026Offer documentSEC
S-4/A · Registration statement, amendedSep 9, 2026Offer documentSEC
S-4 · Registration statementAug 28, 2026Offer documentSEC
4 · Change in ownershipAug 27, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedAug 13, 2026Big-stake noticeSEC
4 · Change in ownershipAug 5, 2026Insider tradeSEC
425Aug 3, 2026Other filingsSEC
425Aug 3, 2026Other filingsSEC
10-Q · Quarterly reportAug 3, 2026Quarterly reportSEC
425Aug 3, 2026Other filingsSEC
8-K · Current reportAug 3, 2026Current reportSEC
425Aug 3, 2026Other filingsSEC
8-K · Current reportAug 3, 2026ResultsSEC
425Aug 3, 2026Other filingsSEC
8-K · Current reportAug 3, 2026Material contractSEC
4 · Change in ownershipJul 13, 2026Insider tradeSEC
144 · Notice of proposed saleJul 10, 2026Other filingsSEC
4 · Change in ownershipJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
144 · Notice of proposed saleJun 11, 2026Other filingsSEC
4 · Change in ownershipJun 10, 2026Insider tradeSEC
144/A · Notice of proposed sale, amendedJun 8, 2026Other filingsSEC
144 · Notice of proposed saleJun 8, 2026Other filingsSEC
8-K · Current reportMay 15, 2026Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
4 · Change in ownershipMay 14, 2026Insider tradeSEC
4 · Change in ownershipMay 14, 2026Insider tradeSEC
4 · Change in ownershipMay 14, 2026Insider tradeSEC
4 · Change in ownershipMay 14, 2026Insider tradeSEC
4 · Change in ownershipMay 14, 2026Insider tradeSEC
4 · Change in ownershipMay 14, 2026Insider tradeSEC
4 · Change in ownershipMay 14, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 13, 2026Big-stake noticeSEC
8-K · Current reportMay 4, 2026Current reportSEC
10-Q · Quarterly reportApr 30, 2026Quarterly reportSEC
8-K · Current reportApr 30, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeApr 28, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeApr 27, 2026Big-stake noticeSEC
ARS · Annual report to shareholdersMar 27, 2026Annual reportSEC
DEFA14A · Additional proxy materialMar 27, 2026Meeting noticeSEC
DEF 14A · Proxy statementMar 27, 2026Meeting noticeSEC
SCHEDULE 13G · Big-stake noticeMar 23, 2026Big-stake noticeSEC
4 · Change in ownershipMar 17, 2026Insider tradeSEC
8-K · Current reportMar 17, 2026Material contractSEC
4 · Change in ownershipMar 13, 2026Insider tradeSEC
8-K · Current reportMar 12, 2026Current reportSEC
8-K · Current reportMar 12, 2026Current reportSEC
4 · Change in ownershipMar 11, 2026Insider tradeSEC
4 · Change in ownershipMar 11, 2026Insider tradeSEC
4 · Change in ownershipMar 5, 2026Insider tradeSEC
4 · Change in ownershipMar 5, 2026Insider tradeSEC
4 · Change in ownershipMar 5, 2026Insider tradeSEC
4 · Change in ownershipMar 5, 2026Insider tradeSEC
10-K · Annual reportFeb 26, 2026Annual reportSEC
8-K · Current reportFeb 26, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 17, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 12, 2026Insider tradeSEC
4 · Change in ownershipFeb 12, 2026Insider tradeSEC
4 · Change in ownershipFeb 12, 2026Insider tradeSEC
4 · Change in ownershipFeb 12, 2026Insider tradeSEC
4 · Change in ownershipFeb 12, 2026Insider tradeSEC
4 · Change in ownershipFeb 12, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 12, 2026Big-stake noticeSEC
4 · Change in ownershipJan 28, 2026Insider tradeSEC
4 · Change in ownershipJan 28, 2026Insider tradeSEC
4 · Change in ownershipJan 28, 2026Insider tradeSEC
4 · Change in ownershipJan 28, 2026Insider tradeSEC
4 · Change in ownershipJan 28, 2026Insider tradeSEC
4 · Change in ownershipJan 28, 2026Insider tradeSEC
4 · Change in ownershipJan 28, 2026Insider tradeSEC
15-12GJan 26, 2026Other filingsSEC
S-8 · Registration statement for employee plansJan 26, 2026Offer documentSEC
S-8 POSJan 26, 2026Offer documentSEC
S-8 POSJan 26, 2026Offer documentSEC
8-K · Current reportJan 26, 2026Material contractSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 8, 2026Big-stake noticeSEC
8-K · Current reportJan 8, 2026Current reportSEC
4 · Change in ownershipJan 7, 2026Insider tradeSEC
4 · Change in ownershipJan 7, 2026Insider tradeSEC
4 · Change in ownershipJan 7, 2026Insider tradeSEC
4 · Change in ownershipJan 7, 2026Insider tradeSEC
4 · Change in ownershipJan 7, 2026Insider tradeSEC
3 · Initial statement of ownershipJan 7, 2026Insider tradeSEC
3 · Initial statement of ownershipJan 7, 2026Insider tradeSEC
3 · Initial statement of ownershipJan 7, 2026Insider tradeSEC
3 · Initial statement of ownershipJan 7, 2026Insider tradeSEC
3 · Initial statement of ownershipJan 7, 2026Insider tradeSEC
3 · Initial statement of ownershipJan 7, 2026Insider tradeSEC
3 · Initial statement of ownershipJan 7, 2026Insider tradeSEC
3 · Initial statement of ownershipJan 7, 2026Insider tradeSEC
3 · Initial statement of ownershipJan 7, 2026Insider tradeSEC
3 · Initial statement of ownershipJan 7, 2026Insider tradeSEC
3 · Initial statement of ownershipJan 7, 2026Insider tradeSEC
3 · Initial statement of ownershipJan 7, 2026Insider tradeSEC
3 · Initial statement of ownershipJan 7, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedDec 30, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedDec 23, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeDec 22, 2025Big-stake noticeSEC
8-K · Current reportDec 22, 2025Current reportSEC
8-K · Current reportDec 18, 2025Management or board changeSEC
8-K · Current reportDec 15, 2025Meeting outcomeSEC
SCHEDULE 13D/A · Big-stake notice, amendedDec 10, 2025Big-stake noticeSEC
8-K · Current reportNov 20, 2025Current reportSEC
8-K · Current reportNov 14, 2025Current reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedNov 13, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 13, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 12, 2025Big-stake noticeSEC
144 · Notice of proposed saleNov 7, 2025Other filingsSEC
SCHEDULE 13D/A · Big-stake notice, amendedNov 5, 2025Big-stake noticeSEC
8-K/A · Current report, amendedOct 30, 2025Current reportSEC
10-Q · Quarterly reportOct 30, 2025Quarterly reportSEC
8-K · Current reportOct 30, 2025ResultsSEC
8-K · Current reportOct 1, 2025Current reportSEC
144 · Notice of proposed saleSep 8, 2025Other filingsSEC
144 · Notice of proposed saleSep 8, 2025Other filingsSEC
SCHEDULE 13D/A · Big-stake notice, amendedSep 5, 2025Big-stake noticeSEC
144 · Notice of proposed saleSep 4, 2025Other filingsSEC
144 · Notice of proposed saleAug 28, 2025Other filingsSEC
8-K · Current reportAug 26, 2025Current reportSEC
8-K · Current reportAug 22, 2025Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 13, 2025Big-stake noticeSEC
8-K/A · Current report, amendedAug 4, 2025Management or board changeSEC
10-Q · Quarterly reportJul 31, 2025Quarterly reportSEC
8-K · Current reportJul 31, 2025ResultsSEC
SCHEDULE 13D/A · Big-stake notice, amendedJul 29, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJul 17, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJul 14, 2025Big-stake noticeSEC
8-K · Current reportJun 30, 2025Current reportSEC
8-K · Current reportJun 24, 2025Management or board changeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJun 18, 2025Big-stake noticeSEC
8-K · Current reportJun 2, 2025Current reportSEC
8-K · Current reportMay 30, 2025Current reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedMay 22, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 13, 2025Big-stake noticeSEC
8-K/A · Current report, amendedMay 9, 2025Meeting outcomeSEC
8-K · Current reportMay 8, 2025Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 6, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 1, 2025Quarterly reportSEC
8-K · Current reportApr 23, 2025ResultsSEC
8-K · Current reportMar 27, 2025Current reportSEC
ARS · Annual report to shareholdersMar 20, 2025Annual reportSEC
SCHEDULE 13G · Big-stake noticeMar 18, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedMar 4, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedMar 4, 2025Big-stake noticeSEC
8-K · Current reportMar 4, 2025Material contractSEC
10-K · Annual reportMar 3, 2025Annual reportSEC
6-K · Report of a foreign issuerMar 3, 2025Current reportSEC
6-K · Report of a foreign issuerFeb 28, 2025Current reportSEC
6-K · Report of a foreign issuerFeb 28, 2025Current reportSEC
6-K · Report of a foreign issuerFeb 28, 2025Current reportSEC
6-K · Report of a foreign issuerFeb 27, 2025Current reportSEC
6-K · Report of a foreign issuerFeb 27, 2025Current reportSEC
6-K · Report of a foreign issuerFeb 27, 2025Current reportSEC
6-K · Report of a foreign issuerFeb 25, 2025Current reportSEC
6-K · Report of a foreign issuerFeb 24, 2025Current reportSEC
6-K/A · Report of a foreign issuer, amendedFeb 20, 2025Current reportSEC
6-K · Report of a foreign issuerFeb 20, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 13, 2025Big-stake noticeSEC
6-K · Report of a foreign issuerFeb 12, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeFeb 6, 2025Big-stake noticeSEC
6-K · Report of a foreign issuerFeb 4, 2025Current reportSEC
6-K · Report of a foreign issuerFeb 4, 2025Current reportSEC
6-K · Report of a foreign issuerFeb 4, 2025Current reportSEC
6-K · Report of a foreign issuerFeb 3, 2025Current reportSEC
6-K · Report of a foreign issuerFeb 3, 2025Current reportSEC
6-K · Report of a foreign issuerJan 28, 2025Current reportSEC
6-K · Report of a foreign issuerJan 28, 2025Current reportSEC
6-K · Report of a foreign issuerJan 28, 2025Current reportSEC

This page holds 200 of 572 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Supernus Pharmaceuticals, Inc.’s releases

Common shares
58,224,143
Fully diluted
58,224,143

Fully diluted

LineShares
Common shares58,224,143

Share count over time

CountShares
Nov 22, 202658,224,143

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
BlackRock9.96M17.1%US$429MSep 30, 2026
Vanguard6.3M10.8%US$271MSep 30, 2026
State Street2.57M4.4%US$111MSep 30, 2026
Armistice Capital, LLC2.55M4.4%US$110MSep 30, 2026
Millennium1.97M3.4%US$84.9MSep 30, 2026
Dimensional1.84M3.2%US$79.3MSep 30, 2026
Rubric Capital Management LP1.74M3.0%US$74.9MSep 30, 2026
Stephens Investment Management Group LLC1.64M2.8%US$70.5MSep 30, 2026
Two Sigma1.63M2.8%US$70MSep 30, 2026
Geode Capital1.53M2.6%US$65.9MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Loomis Sayles & Co L P1.44M2.5%US$61.8MSep 30, 2026
GW&K Investment Management, LLC1.37M2.4%US$59.1MSep 30, 2026
Morgan Stanley1.17M2.0%US$50.4MSep 30, 2026
Renaissance Technologies1.13M1.9%US$48.7MSep 30, 2026
Goldman Sachs1.12M1.9%US$48MSep 30, 2026
Qube Research & Technologies Ltd881K1.5%US$37.9MSep 30, 2026
Citadel829K1.4%US$35.7MSep 30, 2026
Systematic Financial Management LP805K1.4%US$34.6MSep 30, 2026
Schwab724K1.2%US$31.2MSep 30, 2026
Northern Trust707K1.2%US$30.4MSep 30, 2026
Ashford Capital Management Inc617K1.1%US$26.6MSep 30, 2026
Woodline Partners LP610K1.0%US$26.2MSep 30, 2026
Jones Hill Capital LP602K1.0%US$25.9MSep 30, 2026
Bank of America597K1.0%US$25.7MSep 30, 2026
D. E. Shaw & Co., Inc.561K0.96%US$24.1MSep 30, 2026
Point72 Asset Management, L.P.543K0.93%US$23.4MSep 30, 2026
abrdn511K0.88%US$22MSep 30, 2026
UBS494K0.85%US$21.3MSep 30, 2026
Rice Hall James & Associates, LLC477K0.82%US$20.5MSep 30, 2026
Pictet Asset Management Holding SA435K0.75%US$19.1MSep 30, 2026
Schroders374K0.64%US$16.5MSep 30, 2026
Victory Capital373K0.64%US$16.1MSep 30, 2026
BNY373K0.64%US$16MSep 30, 2026
Krensavage Asset Management, LLC351K0.60%US$15.1MSep 30, 2026
Eversept Partners, LP348K0.60%US$15MSep 30, 2026
Fidelity290K0.50%US$12.5MSep 30, 2026
Russell Investments Group, Ltd.288K0.49%US$12.4MSep 30, 2026
Principal278K0.48%US$12MSep 30, 2026
Nuveen266K0.46%US$11.5MSep 30, 2026
Invesco209K0.36%US$9.01MSep 30, 2026
Bruce & Co., Inc.200K0.34%US$8.61MSep 30, 2026
Parkman Healthcare Partners LLC200K0.34%US$8.61MSep 30, 2026
Public Sector Pension Investment Board198K0.34%US$8.3MSep 30, 2026
Mutual Of America Capital Management LLC182K0.31%US$7.85MSep 30, 2026
Ameriprise173K0.30%US$7.45MSep 30, 2026
Aristotle Capital Boston, LLC159K0.27%US$6.85MSep 30, 2026
Third Avenue Management LLC157K0.27%US$6.76MSep 30, 2026
Susquehanna151K0.26%US$6.51MSep 30, 2026
American Century150K0.26%US$6.47MSep 30, 2026
Walleye Capital LLC149K0.26%US$6.4MSep 30, 2026

This page holds 50 of 284 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
iShares Core S&P Small-Cap ETF3.5M6.0%US$163MJun 30, 2026
Vanguard Total Stock Market Index Fund1.75M3.0%US$81.4MJun 30, 2026
iShares Russell 2000 ETF1.46M2.5%US$67.9MJun 30, 2026
Nomura Small Cap Core Fund1.43M2.5%US$66MMay 29, 2026
Vanguard Small-Cap Index Fund1.26M2.2%US$58.8MJun 30, 2026
Vanguard Explorer Fund870K1.5%US$38.8MJul 31, 2026
Vanguard Small-Cap Value Index Fund801K1.4%US$37.3MJun 30, 2026
Vanguard Extended Market Index Fund666K1.1%US$31MJun 30, 2026
Fidelity Small Cap Index Fund613K1.1%US$27.4MJul 31, 2026
State Street(R) SPDR(R) Portfolio S&P 600(TM) Small Cap ETF534K0.92%US$24.8MJun 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Loomis Sayles Small Cap Growth Fund497K0.85%US$23.1MJun 30, 2026
iShares Russell 2000 Value ETF483K0.83%US$22.4MJun 30, 2026
U.S. Targeted Value Portfolio379K0.65%US$16.9MJul 31, 2026
Vanguard Tax-Managed Small-Cap Fund375K0.64%US$17.5MJun 30, 2026
iShares S&P Small-Cap 600 Growth ETF359K0.62%US$16.7MJun 30, 2026
Fidelity Extended Market Index Fund297K0.51%US$13.7MMay 31, 2026
Vanguard Russell 2000 Index Fund284K0.49%US$13.1MMay 31, 2026
Fidelity Enhanced Small Cap Core ETF281K0.48%US$13.1MJun 30, 2026
Schwab U.S. Small-Cap ETF274K0.47%US$12.7MMay 31, 2026
Invesco Pharmaceuticals ETF258K0.44%US$11.5MJul 31, 2026
U.S. Small Cap Portfolio258K0.44%US$11.5MJul 31, 2026
Bridge Builder Small/Mid Cap Growth Fund239K0.41%US$11.1MJun 30, 2026
Dimensional U.S. Targeted Value ETF224K0.38%US$9.99MJul 31, 2026
State Street(R) SPDR(R) S & P 600(TM) Small Cap Growth ETF222K0.38%US$10.3MJun 30, 2026
AMG GW&K Small Cap Core Fund220K0.38%US$10.2MJun 30, 2026
Small Cap Equity Portfolio218K0.37%US$9.72MJul 31, 2026
U.S. Micro Cap Portfolio211K0.36%US$9.4MJul 31, 2026
abrdn U.S. Small Cap Equity Fund209K0.36%US$9.31MJul 31, 2026
Dimensional U.S. Small Cap ETF201K0.34%US$8.97MJul 31, 2026
Vanguard S&P Small-Cap 600 Index Fund198K0.34%US$9.16MMay 31, 2026
Vanguard Health Care Index Fund172K0.30%US$7.94MMay 31, 2026
Dimensional U.S. Core Equity 2 ETF159K0.27%US$7.09MJul 31, 2026
Third Avenue Small-Cap Value Fund157K0.27%US$7MJul 31, 2026
iShares S&P Small-Cap 600 Value ETF156K0.27%US$7.24MJun 30, 2026
iShares U.S. Pharmaceuticals ETF151K0.26%US$7.02MJun 30, 2026
Bruce Fund150K0.26%US$6.98MJun 30, 2026
Victory Integrity Small-Cap Value Fund147K0.25%US$6.84MJun 30, 2026
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF145K0.25%US$6.74MJun 30, 2026
Nuveen Quant Small Cap Equity Fund140K0.24%US$6.26MJul 31, 2026
Schwab Small-Cap Index Fund136K0.23%US$6.09MJul 31, 2026
Avantis U.S. Small Cap Equity ETF129K0.22%US$5.94MMay 31, 2026
Goldman Sachs Small Cap Value Insights Fund122K0.21%US$5.44MJul 31, 2026
American Beacon Stephens Small Cap Growth Fund117K0.20%US$5.44MJun 30, 2026
U.S. Core Equity 2 Portfolio110K0.19%US$4.92MJul 31, 2026
Fidelity Total Market Index Fund108K0.19%US$4.98MMay 31, 2026
Moa Small Cap Value Fund103K0.18%US$4.78MJun 30, 2026
Master Small Cap Index Series102K0.18%US$4.77MJun 30, 2026
Schwab Fundamental U.S. Small Company ETF102K0.17%US$4.69MMay 31, 2026
State Street(R) SPDR(R) S & P 600(TM) Small Cap Value ETF95,5120.16%US$4.44MJun 30, 2026
JNL Small Cap Index Fund89,9920.15%US$4.19MJun 30, 2026

This page holds 50 of 348 holders. Open Shareholders

Big stakes

StakeStakeSharesDateFiling
BlackRock, Inc.14.70%8.2MMar 31, 2025Schedule 13G
Vanguard Portfolio Management LLC5.66%3.26MMar 31, 2026Schedule 13G
Vanguard Capital Management LLC5.03%2.9MMar 31, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Samuel D Isaly
Other companies: Synlogic Inc (Director · Aug 28, 2017 – Aug 28, 2017 · Past); Alpine Immune Sciences Inc (Director · Jul 24, 2017 – Jul 24, 2017 · Past); Whitehawk Therapeutics, Inc. (Director · Mar 15, 2017 – Mar 15, 2017 · Past); Nabriva Therapeutics AG (Director · Dec 30, 2016 – Dec 30, 2016 · Past); Roka Bioscience Inc (Director · Sep 21, 2016 – Sep 21, 2016 · Past); Loxo Oncology Inc (Director · Aug 10, 2016 – Dec 8, 2017 · Past); Audentes Therapeutics Inc (Director · Jul 19, 2016 – Jul 19, 2016 · Past); Cartesian Therapeutics, Inc. (Director · Jun 21, 2016 – Jun 27, 2016 · Past); Corvus Pharmaceuticals, Inc. (Director · May 18, 2016 – Jun 23, 2016 · Past); Intellia Therapeutics, Inc. (Director · May 11, 2016 – May 11, 2016 · Past); Adaptimmune Therapeutics PLC (Director · Jan 1, 2016 – Mar 27, 2017 · Past); Otonomy Inc (Director · Nov 17, 2015 – Nov 25, 2015 · Past); Dimension Therapeutics (Director · Oct 27, 2015 – Oct 27, 2015 · Past); Sierra Oncology Inc (Director · Jul 15, 2015 – Jul 21, 2015 · Past); Palvella Therapeutics, Inc. (Director · Jun 29, 2015 – Jul 6, 2015 · Past); Glaukos Corporation (Director · Jun 24, 2015 – Aug 31, 2017 · Past); Intercept Pharmaceuticals Inc (Director · Apr 9, 2013 – Jul 17, 2015 · Past); Anthera Pharmaceuticals Inc (Director · May 9, 2011 – Jan 30, 2013 · Past); Amarin Corporation plc (Director · Jan 1, 2011 – Sep 4, 2012 · Past); NxStage Medical Inc (Director · Jul 23, 2008 – Dec 9, 2010 · Past); Albireo Pharma Inc (Director · Feb 12, 2008 – Jun 9, 2009 · Past); Aryx Therapeutics Inc (Director · Nov 7, 2007 – Nov 13, 2007 · Past); Insulet Corporation (Director · May 14, 2007 – May 14, 2007 · Past); Volcano Corp (Director · Jun 14, 2006 – Jun 20, 2006 · Past); Given Imaging Ltd (Director · May 24, 2006 – May 24, 2006 · Past); Avanir Pharmaceuticals Inc (Director · Feb 13, 2006 – May 31, 2006 · Past)
Director · May 4, 2012 – May 4, 2012 · Past
Daniel Ninivaggi
Other companies: Indivior Pharmaceuticals, Inc. (Director · Since at least Mar 4, 2025); Garrett Motion Inc. (CHAIRMAN OF THE BOARD · Since at least Apr 30, 2021); Nu Ride Inc (FORMER EXECUTIVE CHAIRMAN, Director · Mar 14, 2024 – Mar 14, 2024 · Past); Navistar International Corporation (Director · Aug 14, 2017 – Sep 30, 2018 · Past); Hertz Global Holdings, Inc (Director · Jun 30, 2016 – Jun 30, 2021 · Past); Herc Holdings Inc. (Director · Sep 15, 2014 – May 18, 2016 · Past); American Railcar Industries Inc (Director · Jun 4, 2013 – Feb 6, 2014 · Past); CVR Refining LP (Director · Jan 16, 2013 – Jan 16, 2013 · Past); CVR Partners, LP (Director · May 10, 2012 – May 10, 2012 · Past); CVR Energy Inc. (Director · May 7, 2012 – May 7, 2012 · Past); Motorola Mobility Holdings Inc (Director · Dec 1, 2010 – May 22, 2012 · Past); XO Group Inc (Director · Aug 10, 2010 – Aug 10, 2010 · Past); Icahn Enterprises L.P. (President, Director · Apr 5, 2010 – Mar 1, 2013 · Past); Federal-Mogul Corp (Director · Mar 18, 2010 – Mar 18, 2010 · Past); CIT Group Inc (Director · Dec 18, 2009 – May 11, 2010 · Past); Lear Corporation (Executive Vice President · Mar 15, 2006 – Mar 14, 2009 · Past)
Director · Since at least Jan 1, 2026
M James Barrett
Other companies: Senseonics Holdings, Inc. (Director · Mar 17, 2016 – May 30, 2019 · Past); Kineta Inc. (Director · Feb 10, 2016 – Jun 15, 2018 · Past); Zosano Pharma Corp (Director · Jan 26, 2015 – Jan 30, 2015 · Past); Loxo Oncology Inc (Director · Jul 31, 2014 – Jul 28, 2015 · Past); Roka Bioscience Inc (Director · Jul 16, 2014 – Jun 28, 2017 · Past); Crescent Biopharma, Inc. (Director · Jan 9, 2014 – May 18, 2018 · Past); Omthera Pharmaceuticals Inc (Director · Jul 18, 2013 – Jul 18, 2013 · Past); Clovis Oncology Inc (Director · Nov 15, 2011 – Oct 11, 2018 · Past); Amicus Therapeutics Inc (Director · Jun 15, 2010 – Jun 12, 2014 · Past); Medimmune Inc (Director · Jun 30, 2006 – Jun 18, 2007 · Past); Pharmion Corp (Director · Jun 8, 2006 – Mar 7, 2008 · Past); Gyre Therapeutics, Inc. (Director · Apr 11, 2006 – Jun 7, 2012 · Past); Inhibitex Inc (Director · Feb 1, 2006 – Feb 13, 2012 · Past); Iomai Corp (Director · Jan 25, 2006 – Aug 4, 2008 · Past)
Director · Apr 30, 2012 – Mar 16, 2016 · Past
David E. Wheadon
Other companies: Indivior Pharmaceuticals, Inc. (Director · Since at least May 13, 2026); Seaport Therapeutics, Inc. (Director · Since at least Apr 30, 2026); Vaxart, Inc. (Director · Since at least Aug 4, 2022); Sotera Health Company (Director · Since at least May 27, 2022); Karuna Therapeutics Inc (Director · Jun 15, 2022 – Mar 18, 2024 · Past); ChemoCentryx Inc. (Director · May 26, 2022 – Oct 20, 2022 · Past)
Director · Since at least Jan 1, 2026
Barbara Ryan
Other companies: Indivior Pharmaceuticals, Inc. (Director · Since at least May 13, 2026); Azitra Inc (Director · Since at least Jun 15, 2023); MiNK Therapeutics, Inc. (Director · Since at least Oct 13, 2021); INVO Fertility, Inc. (Director · Since at least Sep 14, 2020)
Director · Since at least Jan 1, 2026
Mark Stejbach
Other companies: Indivior Pharmaceuticals, Inc. (Director · Since at least May 13, 2026); Flexion Therapeutics Inc (Director · Sep 13, 2016 – Nov 19, 2021 · Past); Alkermes plc (SVP/Chief Comm Off, Alks Inc · Feb 29, 2012 – Mar 1, 2018 · Past); Tengion Inc (VP and Chief Commercial Offcr · Apr 9, 2010 – May 11, 2011 · Past)
INDEPENDENT NON-EXECUTIVE DIRECTOR · Since at least Jan 1, 2026
Jack A Khattar
Other companies: Cognition Therapeutics, Inc. (Director · Since at least Oct 7, 2021); Scpharmaceuticals Inc (Director · Since at least Nov 16, 2017); Tesaro Inc (President, CEO, Director · Mar 29, 2016 – Mar 29, 2016 · Past)
President, CEO, Director · Since at least Apr 30, 2012
Timothy C. Dec
Other companies: CapForce Inc. (Chief Financial Officer · May 4, 2015 – May 17, 2021 · Past); TSS, Inc. (Chief Financial Officer · Aug 20, 2007 – Jun 6, 2012 · Past); Broadwing Corp (SVP Ch. Acct. Officer & Treas. · Mar 20, 2006 – Apr 3, 2006 · Past)
Senior Vice President, Chief Financial Officer · Since at least Aug 23, 2021
Georges Gemayel
Other companies: Disc Medicine, Inc. (Director · Since at least Apr 29, 2021); Momenta Pharmaceuticals Inc (Director · Jun 19, 2019 – Oct 1, 2020 · Past)
INDEPENDENT NON-EXECUTIVE DIRECTOR · Since at least Feb 21, 2020
James Patrick Kelly
Other companies: Novavax, Inc. (EVP, CFO and Treasurer · Since at least Aug 16, 2021); Vanda Pharmaceuticals Inc. (EVP & Chief Financial Officer · Jan 2, 2020 – Mar 2, 2020 · Past)
Executive Vice-President & CFO · Oct 12, 2020 – Feb 19, 2021 · Past
All 35 people
PersonSeat
Patrick Barry
Other companies: Indivior Pharmaceuticals, Inc. (Chief Commercial Officer · May 27, 2025 – Nov 4, 2026 · Past); Endo International PLC (EVP & Pres,Global Comm Ops · Feb 26, 2018 – Mar 29, 2022 · Past)
Chief Commercial Officer · Since at least Jan 1, 2026
Stuart A Kingsley
Other companies: Indivior Pharmaceuticals, Inc. (Director · Since at least May 13, 2026); Scholar Rock Holding Corporation (President and CEO, Director · May 20, 2020 – Feb 1, 2021 · Past)
Director · Since at least Jan 1, 2026
Christian Heidbreder
Other companies: Indivior Pharmaceuticals, Inc. (Chief Scientific Officer · Since at least Jun 11, 2026)
Chief Scientific Officer · Since at least Jan 1, 2026
Frederick M Hudson
Other companies: Scpharmaceuticals Inc (Director · Since at least Jun 18, 2019)
Director · Since at least Feb 21, 2020
Jack A. Khattar
Other companies: Cognition Therapeutics, Inc. (Until Apr 20, 2026 · Past)
President and Chief Executive Officer, Director · Since at least Feb 23, 2026
Juliet Thompson
Other companies: Indivior Pharmaceuticals, Inc. (Director · Since at least May 12, 2026)
INDEPENDENT NON-EXECUTIVE DIRECTOR · Since at least Jan 1, 2026
Keith Humphreys
Other companies: Indivior Pharmaceuticals, Inc. (Director · Since at least May 13, 2026)
INDEPENDENT NON-EXECUTIVE DIRECTOR · Since at least Nov 5, 2026
Ryan Preblick
Other companies: Indivior Pharmaceuticals, Inc. (Chief Financial Officer · Since at least Jun 8, 2026)
Chief Financial Officer · Since at least Jan 1, 2026
Woodrow D Anderson
Other companies: Indivior Pharmaceuticals, Inc. (Chief Accounting Officer · Since at least Aug 5, 2026)
Chief Accounting Officer · Since at least Jan 1, 2026
Bethany SensenigINDEPENDENT NON-EXECUTIVE DIRECTOR · Since at least Nov 5, 2026
Bryan A. RoeckleinSenior Vice President, Chief Business Officer · Since at least Nov 4, 2026
Carrolee BarlowINDEPENDENT NON-EXECUTIVE DIRECTOR · Since at least Jun 27, 2018
Charles W Newhall IIIDirector · Since at least Nov 2, 2026
Frank MottolaSVP, Chief Tech. Ops. Officer · Since at least Feb 21, 2020
Frank MottolaSenior Vice President, Chief Technical Operations Officer · Since at least Nov 4, 2026
Gregory S PatrickSr. VP Chief Financial Officer · Apr 30, 2012 – Nov 9, 2020 · Past
Jeff BozickSenior Vice President, Supply Chain · Since at least Nov 4, 2026
Jonathan RubinSenior Vice President, Chief Medical Officer, Research & Development · Since at least Jan 1, 2021
Kevin EspinozaChief Integrity and Compliance Officer · Since at least Nov 4, 2026
Padmanabh P. BhattSenior Vice President, Chief Scientific Officer, Intellectual Property · Since at least Aug 7, 2025
Roman BradelVice President, Regulatory Affairs · Since at least Nov 4, 2026
Stefan K F SchwabeExecutive Vice President & CMO · Jul 9, 2012 – Dec 21, 2020 · Past
Taylor RaifordSenior Vice President, Sales · Since at least Nov 4, 2026
Todd HorichSenior Vice President, Chief Commercial Officer · Since at least Nov 4, 2026
William Todd HorichSVP, Commercial Operations · Since at least Mar 1, 2026

Open People

Log in to ask 6ix AI your own questions about Supernus Pharmaceuticals, Inc.